Key Takeaways
- Record revenue, margin squeeze: Revenue hit an all-time high of ₹613 crores, but EBITDA margin eroded a couple of percentage points QoQ as raw material cost pass-through lagged.
- CDMO is the growth engine: CDMO sales nearly doubled QoQ, and management reaffirmed 40–50% growth this year and next, with a long-term target of ₹1,000 crores.
- Xanthine held back by logistics, not demand: Shipment constraints suppressed Q2 xanthine sales; dispatch issues are expected to resolve in Q3, and full-year volume is guided to jump 15–20%.
- Capex cycle is peaking: Atali Phase 1B and xanthine projects fully capitalize in H2, pushing up depreciation and operating expenses; total FY27 capex is pegged at ₹350–400 crores with more debt to come.
- What to watch next quarter: Whether the promised margin recovery materializes as pass-through catches up and CDMO scales, the pace of Atali asset utilization, and any update on the peptide/oligo lab build-out.
CDMO: The Growth Story
- Q2 inflection: CDMO sales nearly doubled versus Q1, keeping the business firmly on track for the 40–50% full-year growth target; management expects the business to further grow next year.
- Pipeline is a moving number: The 60-project pipeline constantly refreshes with new additions and clinical-phase deletions; the 80/20 rule applies, with 10–12 key projects expected to drive ₹700–800 crores of the eventual ₹1,000 crore revenue target.
- China Plus One tailwind: A noticeable increase in project count came from work shifting out of China; these were not individually large but the volume of projects is rising.
- Capacity planning in flux: Current dedicated block capacity is planned only for a few projects; if more projects gain visibility, additional manufacturing assets will be needed, with a decision on where and how much coming next year.
- Working capital is the price of growth: CDMO's H2-weighted revenue profile forces inventory build-up in H1, and management is explicit that higher inventory is structural: "we will have to live with the higher inventory overall within our system."
Gogri: "The 10 to 12 projects that we have out of the 60 projects, the 20% projects, will drive INR700 crores to INR800 crores of the revenue for out of the INR1,000 potential that we have overall."
Xanthine: Pricing Strength, Logistics Drag
- Dispatch constraints masked demand: Q2 xanthine sales actually fell slightly, but allied chemistry (classified under the same segment) bumped top-line to keep the segment nearly flat QoQ; roughly 5% of Q2 sales were spillover from the prior quarter due to shipment issues.
- Pricing tailwind intact: Average realization is up 10–15% over last year, and full-year average volume is expected to be 15% higher; pharma and beverage segments offer more pricing stability, while spot segment prices face pressure.
- Volume ramp on track: Full-year volume is guided to jump 15–20% over last year's ~6,000 base; next year, volumes are expected to reach 7,500–8,000, with a gradual climb to ~8,800 (90% utilization of 9,600 nameplate) over two years.
- No more capex, defend the position: Management is happy to maintain the second-largest global capacity position for the next few years with no further xanthine capex planned; full utilization is deliberately not the goal.
- Margin sustainability: Existing absolute margin is expected to sustain at least for next financial year, after which management will reassess.
Gogri: "We had little bit of lower Xanthine sales due to the shipments being held up due to shipment issues, but more sales on allied products. Otherwise, we would have ideally had higher sales in this quarter, but it was restricted due to these dispatch constraints."
API & Intermediates: Recovery Underway
- Steroid block back online: A major block shutdown in Q1 ended, enabling regular API and steroid sales to return in Q2; expanded steroid API capacity is now contributing to production and revenue.
- Volume-led growth: Q2 API growth was largely volume-driven, not pricing-driven, with a quarterly run rate of ₹180 crores for the API plus intermediate segment; H2 is expected to build on a base of ₹180–200 crores per quarter.
- Mix shift toward regulated markets: Some projects are being converted to more regulated markets, which carry higher margins versus ROW and other markets.
- API share declining by design: API's share of total sales has fallen from 43% in FY25 to close to 30% in H1 FY27, not because the business is shrinking but because CDMO and R&D are growing faster; the absolute pie is increasing.
- Growth levers ahead: Anti-diabetic, blood thinners, anti-hypertensives, inhalation steroids, and oncology are the identified growth areas; several patent expiries next financial year will enable product launches with partners, alongside market-share gains via the Alternate Vendor Development programme.
Margins: Squeezed Now, Recovery Promised
- Raw material pass-through lagged: EBITDA margin eroded a couple of percentage points QoQ because raw material costs stayed elevated and cost pass-through to customers took time; pass-through is now happening in xanthine/allied chemistry and some API price increases have been obtained.
- H2 recovery expected: Management stated that overall EBITDA percentage can improve in Q3 and Q4 as higher CDMO sales and continued pass-through flow through.
- Capex will load the P&L: As Atali Phase 1B and caffeine early intermediate capitalize in Q3, operating expenses will start recurring on the P&L; operating leverage should absorb some cost, but EBITDA margin may vary "1 percentage point here or there."
- Gross margin in absolute terms: Management emphasized that absolute gross margins will keep increasing as more quality business is done, even if percentage margin depends on the mix of high raw material pricing (downward pressure) and CDMO (upward).
Gogri: "Overall EBITDA percentage number can improve in the third and fourth quarter."
Capex, Balance Sheet & New Capabilities
- Capex peak: Total FY27 capex is targeted at ₹350–400 crores; total H2 capitalization will not exceed ₹300 crores, with some projects slipping to Q1 next year.
- Debt rising: Debt increased by about ₹150 crores in H1, and more debt will be needed for the remaining ~₹250 crores of FY27 capex.
- Atali build-out: Phase 1A is commercialized and commissioning; Phase 1B trial batches are underway, with full capitalization expected in Q3; the block will serve CDMO plus intermediates, not API, with an asset turn assumption of 1.2–1.4x for the block itself.
- Peptide and oligo labs: Operational labs with all equipment will be ready by end of FY27; experienced peptide teams are already being recruited. Next financial year will be the year of starting and pitching to customers, with firm commentary only after that.
- Modalities beyond small molecules: The company is developing peptides, oligonucleotides, and ADC linkers as new modalities to offer innovator customers, with full disclosure now on the renovated website.
Gogri: "I think next year will be the year where we will do a start, we will pitch to the customers and see how it goes and then I will be able to give you a firm commentary that how we are progressing on this."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| CDMO revenue growth | 40–50% growth over last year | FY27 and FY28 |
| CDMO long-term revenue | ₹1,000 crores (or ₹10 crore, whichever comes first) | Timing dependent on customer approvals |
| Xanthine volume growth | 15–20% jump over last year's ~6,000 volume | FY27 |
| Xanthine capacity utilization | Reach ~8,800 (90% of 9,600 nameplate) | Over next two years |
| Xanthine dispatch constraints | Resolved, sales numbers to increase | Q3 FY27 |
| Atali Phase 1B capitalization | Full capitalization | Q3 FY27 |
| Atali asset utilization | Completely utilized | H2 FY27 |
| Peptide lab operational | Labs with all equipment ready | End of FY27 |
| Total FY27 capex | ₹350–400 crores | FY27 |
| H2 capitalization ceiling | Not to exceed ₹300 crores | H2 FY27 |
| API + intermediate quarterly base | ₹180–200 crores per quarter | H2 FY27 |
| API + intermediate long-term growth | 10–15% every year | Ongoing |
| Xanthine absolute margin | Sustain existing absolute margin | At least through next financial year |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Standalone revenue | ₹613 cr, +47% YoY (highest ever quarterly revenue) |
| Standalone EBITDA | ₹136 cr, +84% YoY |
| Standalone PAT | ₹66 cr, 2.75x YoY |
| Standalone EBITDA margin | 22.2%, vs 17.7% in Q2 FY26 |
| Xanthine derivatives and allied products share | 50% of turnover |
| API and intermediate business share | 30% of turnover |
| CDMO/CMO share | 13% of revenue |
| Export sales share | 59% of total sales |
| CDMO active projects | 59 total, 39 in commercial stages, 20 under development |
| CDMO active customers | 23 |
| CDMO revenue growth target | 40% to 50% over FY26 |
| Xanthine volume growth guidance | ~15% over FY26 (FY26 volume close to 6,000) |
| Xanthine average realization increase | 10% to 15% over FY26 |
| Xanthine capacity utilization | Near 7,000, nameplate capacity 9,600; next year anticipate 7,500 to 8,000 |
| Working capital cycle | 165 to 167 days |
| Cash conversion cycle | 150 to 160 days, baseline for the business |
| Total capex targeted for FY27 | ₹350 cr to ₹400 cr |
| API portfolio | 61 APIs |